News
Eli Lilly Shares Up 13% After Weight Loss Pill Appears As Effective As Ozempic And Mounjaro In Trials
Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily weight loss pill, orforglipron, demonstrated effectiveness consistent with other injectable GLP-1 weight loss drugs, such as Lilly’s Mounjaro and Novo Nordisk’s Ozempic.
2hon MSN
Eli Lilly's (LLY.N) new experimental pill has seen success in its Phase 3 clinical trial. The new pill, orforglipron could ...
U.S. pharma giant Eli Lilly And Co (NYSE:LLY) announced the launch of its popular weight loss drug Mounjaro (tirzepatide) in ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Eli Lilly's Mounjaro enters Indian market, triggering a sharp rise in consultations as obesity rates climb and patients seek ...
A U.S. senator said a GLP-1 drug changed his life — and now he’s calling for widespread access to anti-obesity medications.
Stand-up comedian Amy Schumer has revealed taking Mounjaro for weight loss has made symptoms of perimenopause disappear and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback